Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes pill shows promise in Real-World study

NCT ID NCT05755360

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 291 adults with type 2 diabetes whose blood sugar was not well controlled on their current medication (DPP4i). Participants switched to an oral version of semaglutide, a drug that helps lower blood sugar and may aid weight loss. Over about 5-6 months, researchers measured changes in blood sugar levels and asked participants about their eating habits and diabetes-related well-being. The goal was to see if the switch improved diabetes control in everyday medical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

291 people

The number who actually took part.

Started

Feb 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All Participants who switch from DPP4i treatment to oral semaglutide and meet the eligibility criteria will be included in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * The decision to switch from DPP4i treatment to commercially available oral semaglutide has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study * Participant with last measurement of HbA1c \>= 7.5% at informed consent and treatment initiation visit (V1) or less than or equal to (\<=) 90 days before informed consent and treatment initiation visit (V1) * Treatment naïve to insulin. An exception is short-term insulin treatment for acute illness for a total of \< 14 days Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study * Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days prior to the informed consent and treatment initiation visit (V1) and throughout the duration of the study * Participants with type-1 diabetes * Participants who are pregnant or who become pregnant (or who plan to become pregnant) during the study period * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * Age \< 18 years on the informed consent and treatment initiation visit (V1)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

Contacts and locations

Locations

  • A.O.U. Maggiore della Carità

    Piemonte, 28100, Italy

  • A.O.U. Policlinico Giaccone

    Sicilia, 90127, Italy

  • A.O.U. Policlinico S.Orsola

    Bologna, 40138, Italy

  • ASL Al Di Alessandria - Ospedale Santo Spirito - Casale Monferrato - Cardiologia

    Roma, 00195, Italy

  • ASL Avellino

    Montoro, 83026, Italy

  • ASL Caserta

    Caserta, 81100, Italy

  • ASL Lecce

    Lecce, 73100, Italy

  • ASL Napoli 3 sud

    Palma Campania, 80036, Italy

  • ASL Roma 2 - UOC Cure Primarie Distretto 4

    Roma, 00159, Italy

  • ASST Sette Laghi

    Varese, 21100, Italy

  • Azienda Ospedaliera Cannizzaro

    Catania, 95126, Italy

  • Azienda Sanitaria Locale Cn1

    Cuneo, 12100, Italy

  • Casa di cure Triolo Zancla

    Sicilia, 90133, Italy

  • Fondazione Univ. Policlinico A.Gemelli

    Roma, 00168, Italy

  • INRCA

    Ancona, 60127, Italy

  • Ospedale Generale provinciale

    Province of Macerata, 62100, Italy

  • Ospedale Misericordia

    Grosseto, 58100, Italy

  • Ospedale Pagliari

    Massafra, 74016, Italy

  • Ospedale Pesenti Fenaroli

    Alzano Lombardo, 24022, Italy

  • Ospedale S. Maria della Misericordia

    Udine, 33100, Italy

  • Ospedale San Jacopo

    Pistoia, 51100, Italy

  • Ospedale Treviglio

    Treviglio, 24047, Italy

  • Ospedale centrale L. Bohler

    Bolzano, 39100, Italy

  • P.O. Praia a Mare

    Praia a Mare, 87028, Italy

  • Università degli Studi Foggia

    Foggia, 71122, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.